Developer docs
API playgroundTry for free, no card

Search company profiles

Pumas-AI

Full company profile

uuid0004p92

Namestring
Pumas-AI
Legal namestring
PumasAI, Inc.
Websiteurl
pumas.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Pumas-AI is a privately held pharmacometric software and consulting company headquartered in Dover, Delaware, founded in 2018 by Dr. Joga Gobburu and Dr. Vijay Ivaturi, both formerly faculty at the University of Maryland. The company targets pharmaceutical and biotechnology companies, regulatory agencies, healthcare providers, and academic institutions with a horizontal platform serving the model-informed drug development (MIDD) workflow across preclinical and clinical drug development.

The company's core product is the Pumas platform, a nonlinear mixed effects (NLME) modeling system built on the Julia programming language that supports population PK/PD modeling, bioequivalence analysis, non-compartmental analysis (NCA), and regulatory submission workflows. It is complemented by DeepPumas (scientific machine learning that embeds neural networks inside pharmacometric models), PumasCP (a clinical pharmacology desktop application for study and NCA workflows), and an AI Task Force comprising AskPumas (a RAG-based assistant for pharmacometricians) and PumasAide (an AI coding-agent connector linking OpenAI, Anthropic, Google, and self-hosted models to live Pumas sessions). The company complements software with a Strategic & Scientific Consulting practice providing MIDD, regulatory submission, dose translation, and bridging/extrapolation services.

Revenue is generated through enterprise subscription licensing of Pumas, DeepPumas, and PumasCP to commercial pharma and biotech customers, professional-services fees for consulting engagements, and a freemium Academic Access Program that seeds the developer ecosystem. The company claims 60+ commercial clients, 26+ successful regulatory submissions, 1,400+ scientists across 260 institutions in the academic ecosystem, and three consecutive years of GHP recognition (2024-2026). Notable named customers include Bristol-Myers Squibb, Moderna, Otsuka, Arcus Biosciences, and Relay Therapeutics. No funding rounds are disclosed in the input, suggesting organic or internally financed growth.

Short descriptiontext

Pumas-AI develops the Pumas platform, a Julia-based nonlinear mixed effects modeling suite for pharmacometrics, and provides model-informed drug development consulting to pharmaceutical, biotechnology, regulatory, and academic customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacometric modeling, clinical pharmacology software, drug development analytics, population PK/PD modeling, model-informed drug development
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Software Publishers5132
  • Custom Computer Programming Services541511
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmacometrics Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Licensing
TypeSubscription Recurring
Description

Pumas software products licensed to pharmaceutical, biotechnology companies, and regulatory agencies for commercial drug development use. Includes Pumas, DeepPumas, and PumasCP products.

pumas.ai
2Strategic & Scientific Consulting
TypeProfessional Services
Description

Model-informed drug development consulting services including dose translation, bridging & extrapolation, and regulatory submission support.

pumas.ai
3Academic Access Program
TypeFreemium
Description

Free access to advanced modeling tools for non-commercial research and education purposes.

pumas.ai
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details2 tiers
1Academic/Non-commercial
ModelFreemiumBilling cadenceAnnual
Notes

Complimentary access to advanced modeling tools for non-commercial research & education

pumas.ai
2Commercial Enterprise
ModelSubscriptionBilling cadenceAnnual
Notes

Commercial use requires separate license - pricing not publicly disclosed

pumas.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1DeepPumas
Description

Software suite for individualizable scientific machine learning designed for the healthcare industry. Combines dynamical, statistical, and machine learning modeling to enable full utilization of domain expertise, individualization of predictions, and information hidden in complex data.

deeppumas-docs.pumas.ai
+4 more records
Core offering1 text field

Pumas-AI builds the Pumas software platform, a nonlinear mixed effects (NLME) modeling suite built on Julia that supports population PK/PD modeling, simulation, bioequivalence analysis, and non-compartmental analysis for pharmaceutical drug development. The company supplements its software with the DeepPumas scientific machine learning suite, the AskPumas RAG-based AI assistant, the PumasAide AI coding agent connector, and Strategic & Scientific consulting services for model-informed drug development (MIDD) and regulatory submission support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Saves $1B+ in money and time for 60+ clients
+3 more records
Product overview1 text field

PumasAI offers a integrated portfolio of pharmacometric software products centered on the Pumas NLME modeling platform, supplemented by AI-powered tools (AskPumas, PumasAide), specialized modules (DeepPumas for scientific machine learning, PumasCP for clinical pharmacology workflows), and strategic consulting services. The core Pumas platform handles population PK/PD modeling, simulation, bioequivalence analysis, and NCA, while DeepPumas extends capabilities with neural network embedding for personalized predictions. Pumas for Academia provides free access for non-commercial research. The AI Task Force (AskPumas and PumasAide) brings generative AI and knowledge retrieval capabilities directly into the modeling workflow.

Product and service5 records
1Pumas
CategoryPharmacometrics Software Pharmacometrics Software Pharmacometrics Software
2DeepPumas
CategoryScientific Machine Learning Software Scientific Machine Learning Software Scientific Machine Learning Software
3PumasCP
CategoryClinical Pharmacology Software Clinical Pharmacology Software Clinical Pharmacology Software
4Pumas for Academia
CategoryAcademic Access Program Academic Access Program Academic Access Program
5Strategic & Scientific Consulting
CategoryConsulting Services Consulting Services Consulting Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding partnership with University of Maryland where co-founders Dr. Joga Gobburu and Dr. Vijay Ivaturi were faculty members. The company originated from scientific computing experts at the university.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provides MonolixSuite, GastroPlus, and Immunetrics for PK/PD, PBPK, and QSP modeling plus regulatory science consulting. Closest direct competitor in specialized PK-PD modeling software.

TypeDirect peer
Description

Public, end-to-end model-informed drug development platform offering Phoenix WinNonlin/NLME, consulting, and regulatory services. Most direct and larger-scale competitor to Pumas-AI in pharmacometrics and PBPK.

TypeDirect peer
Description

Pharmacometrics and quantitative systems pharmacology consulting firm using NONMEM, Monolix, R, and other modeling tools. Direct competitor for MIDD consulting engagements.

TypeDirect peer
Description

Quantitative systems pharmacology (QSP) consultancy serving pharma R&D. Adjacent peer overlapping with DeepPumas/Pumas scientific ML positioning.

TypeDirect peer
Description

Lixoft (now part of Simulations Plus) developed MonolixSuite, the most established alternative NLME modeling platform. Direct competitor for population PK/PD software licensing.

TypeBroad incumbent
Description

Public computational chemistry and drug discovery platform extending into predictive modeling and pharma software. Broader incumbent with overlapping computational science customers in pharma R&D.

TypeBroad incumbent
Description

Enterprise biopharma R&D informatics platform with screening, sequencing, and biologics workflows. Broader incumbent in life science software informatics; partial overlap with Pumas in pharma R&D analytics.

TypeBroad incumbent
Description

Provider of software and services for life sciences R&D, including preclinical and clinical workflows. Broader incumbent with overlapping pharma R&D software footprint.

TypeOthers
Description

Commercial sponsor of the Julia language and Pumas ecosystem. Enabling partner/infrastructure provider rather than competitor; closely tied to Pumas-AI's technical foundation.

TypeEmerging player
Description

AI-driven drug discovery company combining high-throughput biology with ML. Emerging player in AI for pharma R&D; thematically comparable as a tech-forward, AI-native approach to drug development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pumas-AI

Pharmacometrics Softwarepumas.ai

Pumas-AI develops the Pumas platform, a Julia-based nonlinear mixed effects modeling suite for pharmacometrics, and provides model-informed drug development consulting to pharmaceutical, biotechnology, regulatory, and academic customers.

What Pumas-AI does

Pumas-AI is a privately held pharmacometric software and consulting company headquartered in Dover, Delaware, founded in 2018 by Dr. Joga Gobburu and Dr. Vijay Ivaturi, both formerly faculty at the University of Maryland. The company targets pharmaceutical and biotechnology companies, regulatory agencies, healthcare providers, and academic institutions with a horizontal platform serving the model-informed drug development (MIDD) workflow across preclinical and clinical drug development.

The company's core product is the Pumas platform, a nonlinear mixed effects (NLME) modeling system built on the Julia programming language that supports population PK/PD modeling, bioequivalence analysis, non-compartmental analysis (NCA), and regulatory submission workflows. It is complemented by DeepPumas (scientific machine learning that embeds neural networks inside pharmacometric models), PumasCP (a clinical pharmacology desktop application for study and NCA workflows), and an AI Task Force comprising AskPumas (a RAG-based assistant for pharmacometricians) and PumasAide (an AI coding-agent connector linking OpenAI, Anthropic, Google, and self-hosted models to live Pumas sessions). The company complements software with a Strategic & Scientific Consulting practice providing MIDD, regulatory submission, dose translation, and bridging/extrapolation services.

Revenue is generated through enterprise subscription licensing of Pumas, DeepPumas, and PumasCP to commercial pharma and biotech customers, professional-services fees for consulting engagements, and a freemium Academic Access Program that seeds the developer ecosystem. The company claims 60+ commercial clients, 26+ successful regulatory submissions, 1,400+ scientists across 260 institutions in the academic ecosystem, and three consecutive years of GHP recognition (2024-2026). Notable named customers include Bristol-Myers Squibb, Moderna, Otsuka, Arcus Biosciences, and Relay Therapeutics. No funding rounds are disclosed in the input, suggesting organic or internally financed growth.

Pumas-AI firmographics

Firmographics
Name
Pumas-AI
Legal name
PumasAI, Inc.
Website
https://pumas.ai
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Pumas-AI develops the Pumas platform, a Julia-based nonlinear mixed effects modeling suite for pharmacometrics, and provides model-informed drug development consulting to pharmaceutical, biotechnology, regulatory, and academic customers.
Ownership category
akta.pro rank

Pumas-AI industry classification

Industry
Product category
Pharmacometrics Software
NAICS
Software Publishers (5132), Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Pharmacometric modeling
  • Clinical pharmacology software
  • Drug development analytics
  • Population PK/PD modeling
  • Model-informed drug development

Where Pumas-AI is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pumas-AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Software Licensing: Pumas software products licensed to pharmaceutical, biotechnology companies, and regulatory agencies for commercial drug development use. Includes Pumas, DeepPumas, and PumasCP products.
  2. Strategic & Scientific Consulting: Model-informed drug development consulting services including dose translation, bridging & extrapolation, and regulatory submission support.
  3. Academic Access Program: Free access to advanced modeling tools for non-commercial research and education purposes.

Pricing tiers

ModelBillingPrice
FreemiumAnnualAcademic/Non-commercial
SubscriptionAnnualCommercial Enterprise

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Pumas-AI product offering

Product offering

Core offering

Pumas-AI builds the Pumas software platform, a nonlinear mixed effects (NLME) modeling suite built on Julia that supports population PK/PD modeling, simulation, bioequivalence analysis, and non-compartmental analysis for pharmaceutical drug development. The company supplements its software with the DeepPumas scientific machine learning suite, the AskPumas RAG-based AI assistant, the PumasAide AI coding agent connector, and Strategic & Scientific consulting services for model-informed drug development (MIDD) and regulatory submission support.

Product overview

PumasAI offers a integrated portfolio of pharmacometric software products centered on the Pumas NLME modeling platform, supplemented by AI-powered tools (AskPumas, PumasAide), specialized modules (DeepPumas for scientific machine learning, PumasCP for clinical pharmacology workflows), and strategic consulting services. The core Pumas platform handles population PK/PD modeling, simulation, bioequivalence analysis, and NCA, while DeepPumas extends capabilities with neural network embedding for personalized predictions. Pumas for Academia provides free access for non-commercial research. The AI Task Force (AskPumas and PumasAide) brings generative AI and knowledge retrieval capabilities directly into the modeling workflow.

Differentiator

Problem solved

Functional benefit

Brands

  • DeepPumas: Software suite for individualizable scientific machine learning designed for the healthcare industry. Combines dynamical, statistical, and machine learning modeling to enable full utilization of domain expertise, individualization of predictions, and information hidden in complex data.
  • PumasCP
  • AskPumas
  • PumasAide
  • Pumas

Products and services

  • Pumas
  • DeepPumas
  • PumasCP
  • Pumas for Academia
  • Strategic & Scientific Consulting

Quantifiable outcome

  • Saves $1B+ in money and time for 60+ clients
  • +3 more outcomes

Companies that use Pumas-AI

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Pumas-AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature7 records

Pumas-AI partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of MarylandcoreStrategic or Co-development PartnerFounding partnership with University of Maryland where co-founders Dr. Joga Gobburu and Dr. Vijay Ivaturi were faculty members. The company originated from scientific computing experts at the university.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Pumas-AI competitors and assessment

Company assessment

Direct peers

  • Simulations Plus: Provides MonolixSuite, GastroPlus, and Immunetrics for PK/PD, PBPK, and QSP modeling plus regulatory science consulting. Closest direct competitor in specialized PK-PD modeling software.
  • Certara: Public, end-to-end model-informed drug development platform offering Phoenix WinNonlin/NLME, consulting, and regulatory services. Most direct and larger-scale competitor to Pumas-AI in pharmacometrics and PBPK.
  • Metrum Research Group: Pharmacometrics and quantitative systems pharmacology consulting firm using NONMEM, Monolix, R, and other modeling tools. Direct competitor for MIDD consulting engagements.
  • Rosa & Co. Quantitative systems pharmacology (QSP) consultancy serving pharma R&D. Adjacent peer overlapping with DeepPumas/Pumas scientific ML positioning.
  • NumPy/PyMC/Pyomo ecosystem (e.g., Lixoxt): Lixoft (now part of Simulations Plus) developed MonolixSuite, the most established alternative NLME modeling platform. Direct competitor for population PK/PD software licensing.

Broad incumbents

  • Schrödinger: Public computational chemistry and drug discovery platform extending into predictive modeling and pharma software. Broader incumbent with overlapping computational science customers in pharma R&D.
  • Genedata: Enterprise biopharma R&D informatics platform with screening, sequencing, and biologics workflows. Broader incumbent in life science software informatics; partial overlap with Pumas in pharma R&D analytics.
  • Instem (SAS-related life science tools): Provider of software and services for life sciences R&D, including preclinical and clinical workflows. Broader incumbent with overlapping pharma R&D software footprint.

Others

  • Julia Computing: Commercial sponsor of the Julia language and Pumas ecosystem. Enabling partner/infrastructure provider rather than competitor; closely tied to Pumas-AI's technical foundation.

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML. Emerging player in AI for pharma R&D; thematically comparable as a tech-forward, AI-native approach to drug development.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Pumas-AI social profiles

Digital presence

Pumas-AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pumas-AI leadership team

Management profile

Number of profiles

Profiles9 records

Pumas-AI subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Pumas-AI funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pumas-AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pumas-AI

What does Pumas-AI do?

Pumas-AI builds the Pumas software platform, a nonlinear mixed effects (NLME) modeling suite built on Julia that supports population PK/PD modeling, simulation, bioequivalence analysis, and non-compartmental analysis for pharmaceutical drug development. The company supplements its software with the DeepPumas scientific machine learning suite, the AskPumas RAG-based AI assistant, the PumasAide AI coding agent connector, and Strategic & Scientific consulting services for model-informed drug development (MIDD) and regulatory submission support.

Is Pumas-AI a public or private company?

Pumas-AI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Pumas-AI founded?

Pumas-AI was founded in 2018. It employs 11 to 50 people.

Where is Pumas-AI based?

Pumas-AI is headquartered in Baltimore, United States, in the North America region.

How does Pumas-AI make money?

Three revenue lines are on record. Software Licensing is the primary driver. The others are strategic & Scientific Consulting and academic Access Program.

Who are Pumas-AI's main competitors?

Direct peers on record are Simulations Plus, Certara, Metrum Research Group, Rosa & Co. and NumPy/PyMC/Pyomo ecosystem (e.g., Lixoxt). Broad incumbents are Schrödinger, Genedata and Instem (SAS-related life science tools). Julia Computing is listed as an others. Recursion Pharmaceuticals is listed as an emerging player.

Does Pumas-AI have an API?

No public API is recorded for Pumas-AI.

What industry is Pumas-AI in?

Pumas-AI's product category is Pharmacometrics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswirePumasAI Unveils Pumas 2.9 with Advanced Scientific Modeling & Simulation for Clinical Pharmacology and PharmacometricsPumasAI announced Pumas 2.9, an update to its clinical pharmacology and pharmacometrics software. The release improves computational performance, estimation stability, reproducibility, and modeling flexibility, including new multithreading and distributed computing. It is available via JuliaHub cloud and desktop, with complimentary access for academic researchers.EIN PresswirePumasAI Unveils Pumas 2.9 with Advanced Scientific Modeling & Simulation for Clinical Pharmacology and PharmacometricsPumasAI announced Pumas 2.9, an update to its clinical pharmacology and pharmacometrics software. The release improves computational performance, estimation stability, reproducibility, and modeling flexibility, and is available via JuliaHub cloud and desktop. It also offers complimentary access to academic researchers.BioSpacePumasAI Brings AI, Scientific Machine Learning and Advanced Pharmacometric Research to ACoP 2026PumasAI announced its scientific program for ACoP 2026, including a full-day pre-conference workshop on AI in pharmacometrics and four poster presentations. The workshop, led by Dr. Niklas Korsbo, will explore strategic foundations of machine learning in pharmacometrics. Attendees can visit Booth #5 to discuss pharmacometrics and AI.EIN PresswirePumasAI Launches New Clinical Pharmacology Webinar Series Showcasing End-to-End AI-Powered PK AnalysisPumasAI launched a four-part webinar series, PumasCP End-to-End, to guide clinical pharmacology teams through AI-powered PK analysis from raw data to regulatory-ready reports. The series begins September 2, 2026, and coincides with PumasCP 3.9, which adds advanced figure support for publication-quality plots.BioSpacePumasAI Helps Launch India’s First Computational Lab for Quantitative Sciences to Advance AI in Drug DevelopmentPumasAI helped establish the Dr. Ramalingam Sankaran Computational Lab for Quantitative Sciences at PSGIMSR in Coimbatore, India, inaugurated on July 13, 2026. The lab, built with SOPHAS and PSGIMSR, provides high-performance computing for AI-driven drug discovery and pharmacometrics. It aims to train researchers and support model-informed drug development.EIN PresswirePumasAI Helps Launch India's First Computational Lab for Quantitative Sciences to Advance AI in Drug DevelopmentPumasAI helped establish the Dr. Ramalingam Sankaran Computational Lab for Quantitative Sciences at PSGIMSR in Coimbatore, India, in collaboration with SOPHAS. The lab, inaugurated July 13, 2026, provides high-performance computing for AI-driven drug discovery and pharmacometrics. It aims to train the next generation of researchers in quantitative sciences.EIN PresswirePumasAI Launches Enterprise AI Transformation Service Proven to Help Pharmaceutical Teams Reach 50% Productivity GrowthPumasAI launched Catalyst, an enterprise AI transformation service for pharmaceutical and biotech organizations. The service aims to deliver up to 50% productivity growth within 12 months by modernizing pharmacometrics workflows. It is delivered through a three-phase engagement model, with PumasAide assisting scientists.BioSpacePumasAI Named Clinical Pharmacology & Pharmacometrics Innovator of the Year 2026 by Global Health & Pharma NewsPumasAI was named Clinical Pharmacology & Pharmacometrics Innovator of the Year 2026 by Global Health & Pharma News, its third consecutive award. The company's tools are used by over 1,400 scientists at 260 institutions, and it launched PumasAide and Pumas 2.8 with AI capabilities.openPR.comBioequivalence Studies Simulators Market is expected to Hit US$ 1.35 billion by 2032 | Major Companies - Simulations Plus, Inc., Certara, Inc., Pumas-AI, Inc., BioPharma Services Inc.DataM Intelligence released a market research report on the Bioequivalence Studies Simulators Market, estimating the market reached US$ 0.85 billion in 2025 and projecting growth to US$ 1.35 billion by 2032 at a CAGR of 6.0%. The report highlights industry developments including regulatory encouragement for virtual bioequivalence analysis in the United States and increased adoption of model-informed drug development in Japan, while listing key players such as Simulations Plus, Certara, Pumas-AI, and BioPharma Services.SpringerLinkAn AI Approach to Generating MIDD Assets Across the Drug Development Continuum - The AAPS JournalThis review article evaluates the integration of Artificial Intelligence and Machine Learning (AI/ML) into Model-Informed Drug Development (MIDD) to enhance efficiency across the drug development continuum. It contrasts traditional MIDD paradigms with emerging AI-driven platforms, specifically highlighting VeriSIM Life's BIOiSIM platform and Pumas-AI's DeepPumas as examples of technologies designed to improve predictive accuracy and decision-making. The analysis suggests that AI/ML approaches can significantly reduce costs and time-to-market by optimizing preclinical and clinical trial stages through better data utilization and simulation.